Home / Pharmaceutical company intelligence
Atco Laboratories Limited logo
Pharmaceutical company intelligence

Atco Laboratories Limited

Pharmaceutical manufacturer · Karachi · Pakistan

Long-established Pakistan pharmaceutical manufacturer developing, formulating and marketing generic medicines from a cGMP-compliant Karachi facility.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
Official website ↗ Official contact ↗
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation23 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check22 Sep 2026Latest source-check date across this published portfolio
Latest effective price date27 Jul 2026Newest effective date among published current price records
Corporate profile evidence5 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Company type
Pharmaceutical manufacturer
Address
B-18, S.I.T.E., Karachi-75700, Pakistan · 75700
Phone
+92 21 111 111 645
Official contact
Contact page ↗
Corporate source details checked
16 Aug 2026
Corporate profile completeness
100%
DRAP manufacturing licenceAs published by the DRAP Licensing Division. DRAP issues this list for stakeholder review and states it is not a reference for litigation, claims or citation.
Formulation 000188 Atco Laboratories Limited · Sindh
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000188 268 linked products · source seen 23 Sep 2026 View source ↗
DSL 025 10 linked products · source seen 23 Sep 2026 View source ↗
Corporate profile source ledger Logo Url source ↗ Contact Page Url source ↗ Logo Source Url source ↗
Location intelligence

Company location

Google Maps
Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx278public portfolio records represented
REG183unique registrations represented
IDX92indexed MedInfoBase presentations
SRC0additional source-observed presentations
R+0registry-only registrations
VER0registry-verified exact registrations
PKR265current validated price records
G94generic molecules in indexed catalogue
DF15dosage-form groups
TA15therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage95%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage86%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixAtco Laboratories LimitedShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/atco-laboratories-limitedGenerated 23 Sep 2026Anti-infectives94 · 34%Cardiovascular51 · 18%Endocrine & metabolic33 · 12%Hematology & thrombosis29 · 10%Dermatology17 · 6%Pain & musculoskeletal12 · 4%CNS & mental health12 · 4%Other therapeutic areas30 · 11%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioAtco Laboratories LimitedDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/atco-laboratories-limitedGenerated 23 Sep 2026278presentationsTablet162 · 58%Injection25 · 9%Suspension23 · 8%Cream20 · 7%Capsule14 · 5%Solution10 · 4%Other forms24 · 9%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionAtco Laboratories LimitedCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/atco-laboratories-limitedGenerated 23 Sep 2026240comparable productsBelow peer median89 · 37%Near peer median64 · 27%Above peer median87 · 36%Company median price position+0.0%Lowest-price equivalents39Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsAtco Laboratories LimitedCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/atco-laboratories-limitedGenerated 23 Sep 2026Nabiqasim Industries (Pvt) Ltd.,50 shared53% overlapValor Pharmaceuticals44 shared47% overlapCCL Pharmaceuticals (Pvt.) Limited39 shared41% overlapTABROS PHARMA (PVT). LTD.39 shared41% overlapZafa Pharmaceutical Laboratories (P…38 shared40% overlapM/s. Genix Pharma (Pvt) Ltd.37 shared39% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives94 products · 34%
Cardiovascular51 products · 18%
Endocrine & metabolic33 products · 12%
Hematology & thrombosis29 products · 10%
Dermatology17 products · 6%
Pain & musculoskeletal12 products · 4%
CNS & mental health12 products · 4%
Oncology & immunology11 products · 4%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Antidiabetic medicines33 products · 12%
Antifungals18 products · 6%
Anticoagulants17 products · 6%
Calcium-channel blockers14 products · 5%
Antivirals13 products · 5%
Angiotensin receptor blockers13 products · 5%
Fluoroquinolone antibacterials11 products · 4%
Topical corticosteroids / anti-inflammatory dermatologics11 products · 4%
Formulation footprint

Dosage forms

Tablet162 products
Injection25 products
Suspension23 products
Cream20 products
Capsule14 products
Solution10 products
Ointment7 products
Drops4 products
Gel4 products
Lotion3 products
Sachet2 products
Inhalation1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 Adrance-MEmpagliflozin + Metformin 19presentations 12.5 mg + 1000 mg, 12.5 mg + 500 mg, 12.5 mg + 850 mg, 5 mg + 1000 mg · Tablet #2 REVOBANRivaroxaban 11presentations 10 mg, 15 mg, 2.5 mg, 20 mg · Tablet #3 ADRANCEEmpagliflozin 10presentations 10 mg, 25 mg · Tablet #4 Tiocardis-AMTelmisartan + Amlodipine 9presentations 40 mg + 10 mg, 40 mg + 5 mg, 80 mg + 10 mg, 80 mg + 5 mg · Tablet #5 ASCARDAcetylsalicylic acid (Aspirin) 8presentations 100 mg, 150 mg, 300 mg, 75 mg · Tablet #6 BISOPROLOLBisoprolol fumarate 8presentations 10 mg, 2.5 mg, 5 mg · Tablet
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median8937% of comparable products
Near market median64within ±5% of median
Above market median8736% of comparable products
Lowest-price equivalents39ties included
Company median price position +0.0% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
SULFAZINE 1%Silver sulfadiazine · Cream · 500g PKR 1.55/g-72.0% vs market median Primox DS 800 mg + 160 mgSulfamethoxazole + Trimethoprim · Tablet · 100's PKR 2.91/tablet-68.5% vs market median Rumafen 200 mgIbuprofen · Tablet · 500's PKR 0.81/tablet-64.9% vs market median SULFAZINE 1 %Silver sulfadiazine · Cream · 250g PKR 1.55/g-59.3% vs market median Rumafen 200 mgIbuprofen · Tablet · 30's PKR 1.00/tablet-56.7% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Nabiqasim Industries (Pvt) Ltd.,365 products · 118 generics 50shared generics Valor Pharmaceuticals219 products · 97 generics 44shared generics CCL Pharmaceuticals (Pvt.) Limited249 products · 99 generics 39shared generics TABROS PHARMA (PVT). LTD.179 products · 65 generics 39shared generics Zafa Pharmaceutical Laboratories (Pvt) Ltd.245 products · 97 generics 38shared generics M/s. Genix Pharma (Pvt) Ltd.297 products · 97 generics 37shared generics
Regulatory & price activity

Observed database signals

Indexed registration numbers183Distinct registrations among indexed, published, presentation-validated products only
Verified price observations279
Products with a verified price278
Products with multiple price observations1
Source records with multiple versions275
Latest portfolio source check22 Sep 2026
Latest effective price date27 Jul 2026
Latest source observation23 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

183 unique registration(s) · 92 indexed presentation(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Intelligence filter: Therapeutic areaAnti-infectives Clear intelligence filters
Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
LEISHMAFOS Miltefosine 50 mg Capsule 56's 088226 PKR 31,063.99 PKR 554.71/capsule Near median
MEGLU MEGLUMINE ANTIMONIATE 1.5 g/5 mL Injection 5's x 5ml 082111 PKR 564.91 PKR 22.60/mL No comparator
MESKAZOLE Mebendazole 100 MG Tablet 60's 100272 PKR 457.51 PKR 7.63/tablet 14% above median
MICRONA Miconazole 1 % Cream 10GM 014208 PKR 94.18 PKR 9.42/g No comparator
OSEFLU Oseltamivir 75 mg Capsule 10's 042126 PKR 2,142.50 PKR 214.25/capsule 78% above median
OXCIN Moxifloxacin 0.5 % Ophthalmic solution 5ml 055601 PKR 638.87 PKR 127.77/mL No comparator
PIPRA Dihydroartemisinin + Piperaquine 15 mg + 120 mg Sachet 16's 073873 PKR 800.26 PKR 50.02/sachet 5% above median
PIPRA Dihydroartemisinin + Piperaquine 40 mg + 320 mg Tablet 8's 073874 PKR 680.22 PKR 85.03/tablet Near median
POXVIR Aciclovir 200 MG/5 mL Oral suspension 60ml 091254 PKR 310.64 PKR 5.18/mL Near median
PRIMOX Sulfamethoxazole + Trimethoprim 400 mg + 80 mg / 10 mL Suspension 50ml 005997 PKR 55.39 PKR 1.11/mL No comparator
PRIMOX Sulfamethoxazole + Trimethoprim 400 mg + 80 mg Tablet 200's 005998 PKR 268.49 PKR 1.34/tablet 52% below median
Primox DS Sulfamethoxazole + Trimethoprim 800 mg + 160 mg Tablet 100's 007385 PKR 290.86 PKR 2.91/tablet 69% below median
PROLOX Ciprofloxacin 3 mg/mL Ophthalmic drops 5ml 024514 PKR 229.63 PKR 45.93/mL 15% above median
PROLOX Ciprofloxacin 500 mg/5 mL Oral suspension 30ml 098621 PKR 295.46 PKR 9.85/mL No comparator
PROLOX Ciprofloxacin 250 mg/5 mL Oral suspension 60ml 098622 PKR 295.46 PKR 4.92/mL 18% above median
PROLOX Ciprofloxacin 250 mg/5 mL Oral suspension 120ml 098622 PKR 443.18 PKR 3.69/mL 20% below median
PROLOX Ciprofloxacin 125 mg/5 mL Oral suspension 60ml 098623 PKR 166.20 PKR 2.77/mL 13% below median
PROLOX Ciprofloxacin 125 mg/5 mL Oral suspension 120ml 098623 PKR 249.30 PKR 2.08/mL 35% below median
Rheumaquin Hydroxychloroquine 200 mg Tablet 30's 047454 PKR 498.58 PKR 16.62/tablet 15% above median
SCABFREE Permethrin 5% Cream 30g 047218 PKR 122.76 PKR 4.09/g Near median
SCABFREE Permethrin 5% Cream 60ml 053466 PKR 168.68 PKR 2.81/mL Near median
SULFAZINE Silver sulfadiazine 1 % Cream 250g 083209 PKR 388.28 PKR 1.55/g 59% below median
SULFAZINE Silver sulfadiazine 1% Cream 500g 083209 PKR 776.59 PKR 1.55/g 72% below median
SULFAZINE Silver sulfadiazine 1 % Cream 20g 083209 PKR 90.41 PKR 4.52/g 28% above median
TERBIDERM Terbinafine 10 mg Solution 10ml 090927 PKR 302.72 PKR 30.27/mL No comparator
TERBIDERM TOPICAL Terbinafine 10 mg/g Solution 60ml 090927 PKR 1,160.03 PKR 19.33/mL 36% below median
TERBIDERM TOPICAL Terbinafine 10 mg/g Solution 20ml 090927 PKR 605.43 PKR 30.27/mL 22% above median
TERBIDERM TOPICAL Terbinafine 10 mg/g Solution 30ml 090927 PKR 908.14 PKR 30.27/mL 22% above median
TRIMALOR ADULT Artesunate + Sulfadoxine + Pyrimethamine 100 mg + 500 mg + 25 mg Tablet 9's 050519 PKR 193.89 PKR 21.54/tablet 11% below median
UMBILICA Chlorhexidine gluconate 7.1 % Gel 5g 084771 PKR 48.54 PKR 9.71/g 15% above median
UMBILICA Chlorhexidine 7.1% Gel 3g x 7's 084771 PKR 188.32 PKR 8.97/g 8% below median
UMBILICA Chlorhexidine gluconate 7.1 % Gel 10g 084771 PKR 97.75 PKR 9.78/g 16% above median
UMBILICA Chlorhexidine 7.1% Gel 3g 084771 PKR 29.13 PKR 9.71/g 8% above median
UMBILICA Chlorhexidine 4 % Solution 20ml 090797 PKR 188.32 PKR 9.42/mL No comparator
UMBILICA Chlorhexidine 4% Solution 30ml 090797 PKR 269.86 PKR 9.00/mL No comparator
VELSOVIR Sofosbuvir + Velpatasvir 100 mg + 400 mg Tablet 14s 089076 PKR 9,232.93 PKR 659.50/tablet 74% below median
VELSOVIR 100mg Velpatasvir 100 mg Tablet 7s 089076 PKR 4,616.46 PKR 659.49/tablet Near median
VELSOVIR 100mg Velpatasvir 100 mg Tablet 28s 089076 PKR 18,465.85 PKR 659.49/tablet Near median
VIREX Ribavirin 200 mg Capsule 10's 027953 PKR 557.67 PKR 55.77/capsule 18% above median
VORINAZ Voriconazole 50 mg Tablet 10's 081096 PKR 738.63 PKR 73.86/tablet 7% below median
VORINAZ Voriconazole 200 mg Tablet 10's 081097 PKR 2,031.24 PKR 203.12/tablet Near median
VORINAZ Voriconazole 200 mg/5 mL Oral suspension 60ml 095087 PKR 2,437.50 PKR 40.63/mL 15% below median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). Atco Laboratories Limited — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 23, 2026, from https://medinfobase.com/company/atco-laboratories-limited/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.